Chemomab Therapeutics Ltd.
http://chemomab.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chemomab Therapeutics Ltd.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Jumble Of Endpoints For Ophthalmic Surgery Analgesics Coming Into Focus At Panel Session
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee may help provide guidance in the increasingly competitive therapeutic space of postoperative ocular pain.
New appointment at XOMA
XOMA (US) has appointed James Neal vice-president of business development. He was most recently acting chief executive officer at Entelos, which was acquired Iconix Biosciences, a privately held company where Mr Neal was CEO.
Looking Forward to Pharma's Decade of Predictive Efficacy
Drug developers can now tap into an array of new preclinical technologies including some that give them the ability to interrogate compounds in a broad biological context-a systems biology approach. In this issue, we profile four start-ups with technologies designed to predict drugs' efficacy: Champions Biotechnology, Cytox, Immuneering and Rhenovia.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Anchiano Therapeutics Israel
- Anchiano Therapeutics Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice